Recent research published in JAMA Surgery highlights increasing delays between cancer diagnosis and treatment initiation in the U.S., spanning nearly a decade. Conducted by the University of California, Los Angeles and Massachusetts General Hospital, the study examined data from over two million patients diagnosed from January 2012 to December 2023.
The focus was on adults with early to locally advanced stages of six prevalent cancers: breast, colon, lung, pancreatic, stomach, and esophageal. These individuals underwent surgery as part of their initial treatment plan.
Geographic Influence on Cancer Mortality
Researchers measured the interval from diagnosis to first treatment, whether surgery or pre-surgical therapy aimed at reducing tumor size. Across all cancer types analyzed, median waiting times increased by more than 10 days over the study period.
The longest increases were seen in stomach cancer, with waits rising from 35 to 49 days, and lung cancer, increasing from 41 to 53 days.
For breast cancer, wait times grew from 34 to 45 days, while colon cancer delays stretched from 20 to 31 days. Pancreatic cancer waits climbed from 23 to 32 days, and esophageal cancer delays increased from 38 to 48 days. A notable portion of patients experienced waits of 60 days or more before commencing treatment.
Dr. Marc Siegel, Fox News senior medical analyst, highlighted the need to address these delays, emphasizing their occurrence even at high-volume academic medical centers.
Equity and Accessibility Concerns
Researchers adjusted for factors such as age and underlying health and noted longer wait times for Black patients, Medicaid recipients, individuals living in lower-income areas, patients who traveled further for care, and those treated at academic centers or high-volume hospitals.
Regional disparities were evident, with the West experiencing longer delays than other areas. For non-breast cancers, robotic surgery use correlated with extended wait times.
Previous medical research has linked surgical treatment delays to increased mortality rates and poorer long-term survival. Drs. Lia D. Delaney and Sherry M. Wren from Stanford School of Medicine commented on the sophistication of cancer care advancements over two decades. They cautioned that as care regionalizes, improvements might inadvertently hinder timely treatment access unless capacity and coordination are optimized.
Study Limitations and Further Research
The study faced limitations due to retrospective analysis of the National Cancer Database, preventing determination of specific reasons behind individual delays, such as scheduling complications, logistical challenges, or personal patient choices.
The database also lacked initial symptom onset or early medical advice information before diagnosis.